{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:57:03Z","timestamp":1792641423739,"version":"4.5.0"},"reference-count":56,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpem-2024-0468_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Sialidosis type 1 is a rare autosomal recessive lysosomal storage disorder caused by pathogenic variants in the <jats:italic>NEU1<\/jats:italic> gene, which encodes the sialic acid-degrading enzyme \u03b1-neuraminidase. Sialidosis type 1 is a milder form with a late-onset phenotype, characterized by progressive myoclonic epilepsy and ataxia with cherry-red spots. Sialidosis type 2 is an early-onset and more severe form presenting with dysmorphic features, hepatosplenomegaly and cognitive delay. Clinical diagnosis is usually supported by increased urinary bound sialic acid excretion and confirmed by genetic analysis or demonstration of \u03b1-neuraminidase enzyme deficiency in cultured fibroblasts. The aim of this study was to present a case of type 1 sialidosis, review the literature, and investigate genotype\u2013phenotype correlations, symptom frequencies, and race-specific mutations in patients diagnosed with type 1 sialidosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2024-0468_abs_002\">\n                  <jats:title>Case presentation<\/jats:title>\n                  <jats:p>We report herein a family of four Turkish siblings affected with sialidosis type 1 associated with a homozygous variant, c.403G&gt;A p. (Asp135Asn), in the <jats:italic>NEU1<\/jats:italic> gene. A systematic literature review on sialidosis type 1 was carried out, by the PubMed database was searched using keywords included sialidosis and\/or <jats:italic>NEU1<\/jats:italic> gene. We selected case reports or series that included genetically confirmed type 1 sialidosis from 1996 to 2023. So far, nearly genetically confirmed 80 patients from unrelated 65 families, more than 40 <jats:italic>NEU1<\/jats:italic> disease causing mutations, have been identified in patients with sialidosis type 1. Among the reported mutations, missense variants are the most common, and few nonsense, frameshift, exonic duplications or small deletions have been reported. c.239C&gt;T p. (Pro80Leu) variant in Chinese and Japanese patients, c.649G&gt;A p. (Val217Met) variant in Japanese patients, c.880C&gt;T p. (Arg294Cys) variant in Indian patients, c.629C&gt;T p. (Pro210Leu) variant in Ecuadorian patients, c.982G&gt;A p. (Gly328Ser) variant in Italian patients, and c.403G&gt;A p (Asp135Asn) and c.625del p. (Glu209Serfs*94) variants in Turkish patients were found higher.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2024-0468_abs_003\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Race-specific variants were found with higher percentages in certain populations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpem-2024-0468","type":"journal-article","created":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T13:42:06Z","timestamp":1735479726000},"page":"176-186","source":"Crossref","is-referenced-by-count":5,"title":["Sialidosis type 1 in a Turkish family: a case report and review of literatures"],"prefix":"10.1515","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1401-5233","authenticated-orcid":false,"given":"Mustafa","family":"K\u0131l\u0131\u00e7","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Metabolism Unit , Ankara Etlik City Hospital , Ankara , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7212-6866","authenticated-orcid":false,"given":"Suzan","family":"\u0130cil","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Metabolism Unit , Ankara Etlik City Hospital , Ankara , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3886-3808","authenticated-orcid":false,"given":"Abdullah","family":"Sezer","sequence":"additional","affiliation":[{"name":"Department of Genetics , Ankara Etlik City Hospital , Ankara , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7906-4801","authenticated-orcid":false,"given":"\u00d6znur","family":"Kaya-G\u00fcne\u015f","sequence":"additional","affiliation":[{"name":"Department of Genetics , Ankara Etlik City Hospital , Ankara , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2137-7467","authenticated-orcid":false,"given":"Selim S.","family":"Como\u011flu","sequence":"additional","affiliation":[{"name":"Department of Neurology , Ankara Etlik City Hospital , Ankara , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"2025020411462959198_j_jpem-2024-0468_ref_001","doi-asserted-by":"crossref","unstructured":"Loren, DJ, Campos, Y, D\u2019Azzo, A, Wyble, L, Grange, DK, Gilbert-Barness, E, et al.. Sialidosis presenting as severe nonimmune fetal hydrops is associated with two novel mutations in lysosomal alpha-neuraminidase. J Perinatol 2005;25:491\u20134. https:\/\/doi.org\/10.1038\/sj.jp.7211335.","DOI":"10.1038\/sj.jp.7211335"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_002","doi-asserted-by":"crossref","unstructured":"McKellar, MJ, Hidajat, RR, Elder, MJ. Acute ocular methanol toxicity: clinical and electrophysiological features. Aust NZ J Ophthalmol 1997;25:225\u201330. https:\/\/doi.org\/10.1111\/j.1442-9071.1997.tb01397.x.","DOI":"10.1111\/j.1442-9071.1997.tb01397.x"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_003","doi-asserted-by":"crossref","unstructured":"Annunziata, I, Patterson, A, Helton, D, Hu, H, Moshiach, S, Gomero, E, et al.. Lysosomal NEU1 deficiency affects amyloid precursor protein levels and amyloid-\u03b2 secretion via deregulated lysosomal exocytosis. Nat Commun 2013;4:2734. https:\/\/doi.org\/10.1038\/ncomms3734.","DOI":"10.1038\/ncomms3734"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_004","unstructured":"Simon, J, Frits, AW. Glycosaminoglycans and oligosaccharides disorders: glycosaminoglycans synthesis defects, mucopolysaccharidoses, oligosaccharidoses and sialic acid disorders. In: Saudubray, JM, Baumgartner, MR, Garc\u00eda-Cazorla, \u00c1, Walter, JH, editors. Inborn Metabolic Diseases Diagnosis and Treatment, 7th ed. Germany: Springer Nature; 2022:778 p."},{"key":"2025020411462959198_j_jpem-2024-0468_ref_005","doi-asserted-by":"crossref","unstructured":"Yogalingam, G, Bonten, EJ, van de Vlekkert, D, Hu, H, Moshiach, S, Connell, SA, et al.. Neuraminidase 1 is a negative regulator of lysosomal exocytosis. Dev Cell 2008;15:74\u201386. https:\/\/doi.org\/10.1016\/j.devcel.2008.05.005.","DOI":"10.1016\/j.devcel.2008.05.005"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_006","doi-asserted-by":"crossref","unstructured":"Sobral, I, Cachulo Mda, L, Figueira, J, Silva, R. Sialidosis type I: ophthalmological findings. BMJ Case Rep 2014. https:\/\/doi.org\/10.1136\/bcr-2014-205871.","DOI":"10.1136\/bcr-2014-205871"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_007","doi-asserted-by":"crossref","unstructured":"D\u2019Azzo, A, Machado, E, Annunziata, I. Pathogenesis, emerging therapeutic targets and treatment in sialidosis. Expert Opin Orphan Drugs 2015;3:491\u2013504. https:\/\/doi.org\/10.1517\/21678707.2015.1025746.","DOI":"10.1517\/21678707.2015.1025746"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_008","doi-asserted-by":"crossref","unstructured":"Coppola, A, Ianniciello, M, Vanli-Yavuz, EN, Rossi, S, Simonelli, F, Castellotti, B, et al.. Diagnosis and management of type 1 sialidosis: clinical insights from long-term care of four unrelated patients. Brain Sci 2020;10:506. https:\/\/doi.org\/10.3390\/brainsci10080506.","DOI":"10.3390\/brainsci10080506"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_009","doi-asserted-by":"crossref","unstructured":"Han, X, Wu, S, Wang, M, Li, H, Huang, Y, Sui, R. Genetic and clinical characterization of mainland Chinese patients with sialidosis type 1. Mol Genet Genomic Med 2020;8:e1316. https:\/\/doi.org\/10.1002\/mgg3.1316.","DOI":"10.1002\/mgg3.1316"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_010","doi-asserted-by":"crossref","unstructured":"Lv, RJ, Li, TR, Zhang, YD, Shao, XQ, Wang, Q, Jin, LR. Clinical and genetic characteristics of type I sialidosis patients in mainland China. Ann Clin Transl Neurol 2020;7:911\u201323. https:\/\/doi.org\/10.1002\/acn3.51058.","DOI":"10.1002\/acn3.51058"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_011","doi-asserted-by":"crossref","unstructured":"Franceschetti, S, Uziel, G, Di Donato, S, Caimi, L, Avanzini, G. Cherry-red spot myoclonus syndrome and alpha-neuraminidase deficiency: neurophysiological, pharmacological and biochemical study in an adult. J Neurol Neurosurg Psychiatry 1980;43:934\u201340. https:\/\/doi.org\/10.1136\/jnnp.43.10.934.","DOI":"10.1136\/jnnp.43.10.934"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_012","doi-asserted-by":"crossref","unstructured":"Bonten, E, Van Der Spoel, A, Fornerod, M, Grosveld, G, D\u2019Azzo, A. Characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder sialidosis. Genes Dev 1996;10:3156\u201369. https:\/\/doi.org\/10.1101\/gad.10.24.3156.","DOI":"10.1101\/gad.10.24.3156"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_013","doi-asserted-by":"crossref","unstructured":"Milner, CM, Smith, SV, Carrillo, MB, Taylor, GL, Hollinshead, M, Campbell, RD. Identification of a sialidase encoded in the human major histocompatibility complex. J Biol Chem 1997;272:4549\u201358. https:\/\/doi.org\/10.1074\/jbc.272.7.4549.","DOI":"10.1074\/jbc.272.7.4549"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_014","doi-asserted-by":"crossref","unstructured":"M\u00fctze, U, B\u00fcrger, F, Hoffmann, J, Tegetmeyer, H, Heichel, J, Nickel, P, et al.. Multigene panel next generation sequencing in a patient with cherry red macular spot: identification of two novel mutations in NEU1 gene causing sialidosis type I associated with mild to unspecific biochemical and enzymatic findings. Mol Genet Metab Rep 2016;10:1\u20134. https:\/\/doi.org\/10.1016\/j.ymgmr.2016.11.004.","DOI":"10.1016\/j.ymgmr.2016.11.004"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_015","doi-asserted-by":"crossref","unstructured":"Fan, SP, Lee, NC, Lin, CH. Clinical and electrophysiological characteristics of a type 1 sialidosis patient with a novel deletion mutation in NEU1 gene. J Formos Med Assoc 2020;119:406\u201312. https:\/\/doi.org\/10.1016\/j.jfma.2019.07.017.","DOI":"10.1016\/j.jfma.2019.07.017"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_016","doi-asserted-by":"crossref","unstructured":"Kojovic, M, Cordivari, C, Bhatia, K. Myoclonic disorders: a practical approach for diagnosis and treatment. Ther Adv Neurol Disord 2011;4:47\u201362. https:\/\/doi.org\/10.1177\/1756285610395653.","DOI":"10.1177\/1756285610395653"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_017","doi-asserted-by":"crossref","unstructured":"Naganawa, Y, Itoh, K, Shimmoto, M, Takiguchi, K, Doi, H, Nishizawa, Y, et al.. Molecular and structural studies of Japanese patients with sialidosis type 1. J Hum Genet 2000;45:241\u20139. https:\/\/doi.org\/10.1007\/s100380070034.","DOI":"10.1007\/s100380070034"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_018","doi-asserted-by":"crossref","unstructured":"Bonten, EJ, Arts, WF, Beck, M, Covanis, A, Donati, MA, Parini, R, et al.. Novel mutations in lysosomal neuraminidase identify functional domains and determine clinical severity in sialidosis. Hum Mol Genet 2000;9:2715\u201325. https:\/\/doi.org\/10.1093\/hmg\/9.18.2715.","DOI":"10.1093\/hmg\/9.18.2715"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_019","doi-asserted-by":"crossref","unstructured":"Palmeri, S, Villanova, M, Malandrini, A, van Diggelen, OP, Huijmans, JG, Ceuterick, C, et al.. Type I sialidosis: a clinical, biochemical and neuroradiological study. Eur Neurol 2000;43:88\u201394. https:\/\/doi.org\/10.1159\/000008141.","DOI":"10.1159\/000008141"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_044","doi-asserted-by":"crossref","unstructured":"Itoh, K, Naganawa, Y, Matsuzawa, F, Aikawa, S, Doi, H, Sasagasako, N, et al.. Novel missense mutations in the human lysosomal sialidase gene in sialidosis patients and prediction of structural alterations of mutant enzymes. J Hum Genet 2002;47:29\u201337. https:\/\/doi.org\/10.1007\/s10038-002-8652-7.","DOI":"10.1007\/s10038-002-8652-7"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_020","unstructured":"Sakazume, Y, Tanaka, M, Isobe, I, Tominaga, R, Nanba, E, Okamoto, K. A case of middle-aged onset sialidosis type I. Rinsho Shinkeigaku 2004;44:541\u20134."},{"key":"2025020411462959198_j_jpem-2024-0468_ref_021","doi-asserted-by":"crossref","unstructured":"Lai, SC, Chen, RS, Wu Chou, YH, Chang, HC, Kao, LY, Huang, YZ, et al.. A longitudinal study of Taiwanese sialidosis type 1: an insight into the concept of cherry-red spot myoclonus syndrome. Eur J Neurol 2009;16:912\u20139. https:\/\/doi.org\/10.1111\/j.1468-1331.2009.02622.x.","DOI":"10.1111\/j.1468-1331.2009.02622.x"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_022","unstructured":"Ranganath, P, Sharma, V, Danda, S, Nandineni, MR, Dalal, AB. Novel mutations in the neuraminidase-1 (NEU1) gene in two patients of sialidosis in India. Indian J Med Res 2012;136:1048\u201350."},{"key":"2025020411462959198_j_jpem-2024-0468_ref_023","doi-asserted-by":"crossref","unstructured":"Sekijima, Y, Nakamura, K, Kishida, D, Narita, A, Adachi, K, Ohno, K, et al.. Clinical and serial MRI findings of a sialidosis type I patient with a novel missense mutation in the NEU1 gene. Intern Med 2013;52:119\u201324. https:\/\/doi.org\/10.2169\/internalmedicine.52.8901.","DOI":"10.2169\/internalmedicine.52.8901"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_024","doi-asserted-by":"crossref","unstructured":"Urbanski, G, Bekri, S, Barth, M, Verny, C, lavigne, C. A case of type I sialidosis with osteonecrosis revealing a new mutation in NEU1. J Inborn Errors Metab Screening 2014. https:\/\/doi.org\/10.1177\/2326409814543468.","DOI":"10.1177\/2326409814543468"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_025","doi-asserted-by":"crossref","unstructured":"Canafoglia, L, Robbiano, A, Pareyson, D, Panzica, F, Nanetti, L, Giovagnoli, AR, et al.. Expanding sialidosis spectrum by genome-wide screening: NEU1 mutations in adult-onset myoclonus. Neurology 2014;82:2003\u20136. https:\/\/doi.org\/10.1212\/WNL.0000000000000482.","DOI":"10.1212\/WNL.0000000000000482"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_026","doi-asserted-by":"crossref","unstructured":"Zou, W, Wang, X, Tian, G. Fundus autofluorescence and optical coherence tomography of a macular cherry-red spot in a case report of sialidosis. BMC Ophthalmol 2016;16:30. https:\/\/doi.org\/10.1186\/s12886-016-0201-9.","DOI":"10.1186\/s12886-016-0201-9"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_027","doi-asserted-by":"crossref","unstructured":"Yavuz, V, Ebru, N, G\u00fcne\u015f, A, Zeliha, M, Mikko, M, Nerses, B, et al.. Progressive myoclonic epilepsy and NEU1 mutation: a different phenotypic case. Turk J Neurol 2016;22:84\u20137. https:\/\/doi.org\/10.4274\/tnd.32650.","DOI":"10.4274\/tnd.32650"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_028","doi-asserted-by":"crossref","unstructured":"Schene, IF, Kalinina, AV, De Sain-van der Velden, M, Van Gassen, KL, Cuppen, I, Van Hasselt, PM, et al.. Pitfalls in diagnosing neuraminidase deficiency: psychosomatics and normal sialic acid excretion. JIMD Rep 2016;25:9\u201313. https:\/\/doi.org\/10.1007\/8904_2015_472.","DOI":"10.1007\/8904_2015_472"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_029","doi-asserted-by":"crossref","unstructured":"Gowda, VK, Srinivasan, VM, Benakappa, N, Benakappa, A. Sialidosis type 1 with a novel mutation in the neuraminidase-1 (NEU1) gene. Indian J Pediatr 2017;84:403\u20134. https:\/\/doi.org\/10.1007\/s12098-016-2286-9.","DOI":"10.1007\/s12098-016-2286-9"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_030","doi-asserted-by":"crossref","unstructured":"Aravindhan, A, Veerapandiyan, A, Earley, C, Thulasi, V, Kresge, C, Kornitzer, J. Child Neurology: type 1 sialidosis due to a novel mutation in NEU1 gene. Neurology 2018;90:622\u20134. https:\/\/doi.org\/10.1212\/WNL.0000000000005209.","DOI":"10.1212\/WNL.0000000000005209"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_031","doi-asserted-by":"crossref","unstructured":"Hu, SC, Hung, KL, Chen, HJ, Lee, WT. Seizure remission and improvement of neurological function in sialidosis with perampanel therapy. Epilepsy Behav Case Rep 2018;10:32\u20134. https:\/\/doi.org\/10.1016\/j.ebcr.2018.02.005.","DOI":"10.1016\/j.ebcr.2018.02.005"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_032","doi-asserted-by":"crossref","unstructured":"Wang, IH, Lin, TY, Kao, ST. Optical coherence tomography features in a case of Type I sialidosis. Taiwan J Ophthalmol 2017;7:108\u201311. https:\/\/doi.org\/10.4103\/tjo.tjo_53_17.","DOI":"10.4103\/tjo.tjo_53_17"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_033","doi-asserted-by":"crossref","unstructured":"Mohammad, AN, Bruno, KA, Hines, S, Atwal, PS. Type 1 sialidosis presenting with ataxia, seizures and myoclonus with no visual involvement. Mol Genet Metab Rep 2018;15:11\u201314. https:\/\/doi.org\/10.1016\/j.ymgmr.2017.12.005.","DOI":"10.1016\/j.ymgmr.2017.12.005"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_034","doi-asserted-by":"crossref","unstructured":"Gultekin, M, Bayramov, R, Karaca, C, Acer, N. Sialidosis type I presenting with a novel mutation and advanced neuroimaging features. Neurosciences 2018;23:57\u201361. https:\/\/doi.org\/10.17712\/nsj.2018.1.20170328.","DOI":"10.17712\/nsj.2018.1.20170328"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_035","doi-asserted-by":"crossref","unstructured":"Ahn, JH, Kim, AR, Lee, C, Kim, NKD, Kim, NS, Park, WY, et al.. Type 1 sialidosis patient with a novel deletion mutation in the NEU1 gene: case report and literature review. Cerebellum 2019;18:659\u201364. https:\/\/doi.org\/10.1007\/s12311-019-1005-2.","DOI":"10.1007\/s12311-019-1005-2"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_036","doi-asserted-by":"crossref","unstructured":"Bou Ghannam, AS, Mehner, LC, Pelak, VS. Sialidosis type 1 without cherry-red spot. J Neuro Ophthalmol 2019;39:388\u201390. https:\/\/doi.org\/10.1097\/WNO.0000000000000773.","DOI":"10.1097\/WNO.0000000000000773"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_037","doi-asserted-by":"crossref","unstructured":"Rossi, S, Gesualdo, C, Tartaglione, A, Bilo, L, Coppola, A, Simonelli, F. Bergmeister\u2019s papilla in a young patient with type 1 sialidosis: case report. BMC Ophthalmol 2020;20:356. https:\/\/doi.org\/10.1186\/s12886-020-01628-1.","DOI":"10.1186\/s12886-020-01628-1"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_050","doi-asserted-by":"crossref","unstructured":"Wang, F, Lin, L, Hu, J, Zhang, J, Wang, K. Neurophysiolgical implications in sialidosis type 1: a case report. Int J Neurosci 2022;132:589\u201392. https:\/\/doi.org\/10.1080\/00207454.2020.1829615.","DOI":"10.1080\/00207454.2020.1829615"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_038","doi-asserted-by":"crossref","unstructured":"Riboldi, GM, Martone, J, Rizzo, JR, Hudson, TE, Rucker, JC, Frucht, SJ. Looking \u201ccherry red spot myoclonus\u201d in the eyes: clinical phenotype, treatment response, and eye movements in sialidosis type 1. Tremor Other Hyperkinet Mov (N Y) 2021;11:53. https:\/\/doi.org\/10.5334\/tohm.652.","DOI":"10.5334\/tohm.652"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_039","doi-asserted-by":"crossref","unstructured":"Mukherjee, D, Bhattacharya, S, Pattnaik, S, Gupta, S, Ray, BK, Biswas, A. Ataxia and myoclonus with a cherry-red spot unfurling an unusual phenotypic presentation of sialidosis type 1. J Mov Disord 2021;14:256\u20138. https:\/\/doi.org\/10.14802\/jmd.20119.","DOI":"10.14802\/jmd.20119"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_040","doi-asserted-by":"crossref","unstructured":"Neeraja, K, Holla, VV, Prasad, S, Surisetti, BK, Rakesh, K, Kamble, N, et al.. Sialidosis type I without a cherry red spot- is there a genetic basis? J Mov Disord 2021;14:65\u20139. https:\/\/doi.org\/10.14802\/jmd.20083.","DOI":"10.14802\/jmd.20083"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_041","doi-asserted-by":"crossref","unstructured":"Cao, LX, Liu, Y, Song, ZJ, Zhang, BR, Long, WY, Zhao, GH. Compound heterozygous mutations in the neuraminidase 1 gene in type 1 sialidosis: a case report and review of literature. World J Clin Cases 2021;9:623\u201331. https:\/\/doi.org\/10.12998\/wjcc.v9.i3.623.","DOI":"10.12998\/wjcc.v9.i3.623"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_042","doi-asserted-by":"crossref","unstructured":"Me\u015fen, S, Batur, M, Ozer, MD. A novel spot mutation leading to sialidosis type 1-myoclonus syndrome and optical coherence tomography findings. Arq Bras Oftalmol 2023:S0004\u201327492023005001203. https:\/\/doi.org\/10.5935\/0004-2749.2022-0069.","DOI":"10.5935\/0004-2749.2022-0069"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_043","doi-asserted-by":"crossref","unstructured":"Sahoo, LK, Kota, V, Panigrahi, PK, Pattnaik, S, Mishra, AP, Sahoo, SK, et al.. Novel pathogenic variant in the NEU1 gene in a patient with sialidosis with progressive myoclonus ataxia with cherry-red spot. Neurology 2023;101:861\u20132. https:\/\/doi.org\/10.1212\/WNL.0000000000207715.","DOI":"10.1212\/WNL.0000000000207715"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_045","doi-asserted-by":"crossref","unstructured":"Franceschetti, S, Canafoglia, L. Sialidoses. Epileptic Disord 2016;18:89\u201393. https:\/\/doi.org\/10.1684\/epd.2016.0845.","DOI":"10.1684\/epd.2016.0845"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_046","doi-asserted-by":"crossref","unstructured":"Spranger, J, Gehler, J, Cantz, M, Opitz, JM. Mucolipidosis I\u2013a sialidosis. Am J Med Genet 1977;1:21\u20139. https:\/\/doi.org\/10.1002\/ajmg.1320010104.","DOI":"10.1002\/ajmg.1320010104"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_047","doi-asserted-by":"crossref","unstructured":"Chen, CM, Lai, SC, Chen, IC, Hsu, KC, Lyu, RK, Ro, LS, et al.. First report of two Taiwanese siblings with sialidosis type I: a 10-year follow-up study. J Neurol Sci 2006;247:65\u20139. https:\/\/doi.org\/10.1016\/j.jns.2006.03.013.","DOI":"10.1016\/j.jns.2006.03.013"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_048","doi-asserted-by":"crossref","unstructured":"Kersten, HM, Roxburgh, RH, Danesh-Meyer, HV, Hutchinson, DO. Optical coherence tomography findings in a patient with type 1 sialidosis. J Clin Neurosci 2016;31:199\u2013201. https:\/\/doi.org\/10.1016\/j.jocn.2016.02.015.","DOI":"10.1016\/j.jocn.2016.02.015"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_049","doi-asserted-by":"crossref","unstructured":"Caciotti, A, Melani, F, Tonin, R, Cellai, L, Catarzi, S, Procopio, E, et al.. Type I sialidosis, a normosomatic lysosomal disease, in the differential diagnosis of late-onset ataxia and myoclonus: an overview. Mol Genet Metabol 2020;129:47\u201358. https:\/\/doi.org\/10.1016\/j.ymgme.2019.09.005.","DOI":"10.1016\/j.ymgme.2019.09.005"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_051","doi-asserted-by":"crossref","unstructured":"Canafoglia, L, Franceschetti, S, Uziel, G, Ciano, C, Scaioli, V, Guerrini, R, et al.. Characterization of severe action myoclonus in sialidoses. Epilepsy Res 2011;94:86\u201393. https:\/\/doi.org\/10.1016\/j.eplepsyres.2011.01.013.","DOI":"10.1016\/j.eplepsyres.2011.01.013"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_052","doi-asserted-by":"crossref","unstructured":"Ferlazzo, E, Trenite, DK, Haan, GJ, Felix Nitschke, F, Ahonen, S, Gasparini, S, et al.. Update on pharmacological treatment of progressive myoclonus epilepsies. Curr Pharmaceut Des 2017;23:5662\u20136. https:\/\/doi.org\/10.2174\/1381612823666170809114654.","DOI":"10.2174\/1381612823666170809114654"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_053","doi-asserted-by":"crossref","unstructured":"Yagi, Y, Machida, A, Toru, S, Kobayashi, T, Uchihara, T. Sialidosis type I with neoplasms in siblings: the first clinical cases. Neurol Sci 2011;32:737\u20138. https:\/\/doi.org\/10.1007\/s10072-010-0392-4.","DOI":"10.1007\/s10072-010-0392-4"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_054","doi-asserted-by":"crossref","unstructured":"O\u2019Leary, EM, Igdoura, SA. The therapeutic potential of pharmacological chaperones and proteosomal inhibitors, Celastrol and MG132 in the treatment of sialidosis. Mol Genet Metabol 2012;107:173\u201385. https:\/\/doi.org\/10.1016\/j.ymgme.2012.07.013.","DOI":"10.1016\/j.ymgme.2012.07.013"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_055","doi-asserted-by":"crossref","unstructured":"Mosca, R, van de Vlekkert, D, Campos, Y, Fremuth, LE, Cadaoas, J, Koppaka, V, et al.. Conventional and unconventional therapeutic strategies for sialidosis type I. J Clin Med 2020;9:695. https:\/\/doi.org\/10.3390\/jcm9030695.","DOI":"10.3390\/jcm9030695"},{"key":"2025020411462959198_j_jpem-2024-0468_ref_056","doi-asserted-by":"crossref","unstructured":"Bonten, EJ, Yogalingam, G, Hu, H, Gomero, E, Van de Vlekkert, D, D\u2019Azzo, A. Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis. Biochim Biophys Acta 2013;1832:1784\u201392. https:\/\/doi.org\/10.1016\/j.bbadis.2013.06.002.","DOI":"10.1016\/j.bbadis.2013.06.002"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2024-0468\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2024-0468\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T11:48:01Z","timestamp":1738669681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2024-0468\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":56,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,12,17]]},"published-print":{"date-parts":[[2025,2,25]]}},"alternative-id":["10.1515\/jpem-2024-0468"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2024-0468","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]}}}